In metastatic hormone-sensitive prostate cancer (mHSPC), phosphatase and tensin homolog (PTEN) deficiency results in phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway activation, providing an independent proliferative drive, which cannot be suppressed by androgen receptor pathway inhibitors (ARPIs), resulting in worse outcomes. Dual inhibition of PI3K/AKT and AR pathways with capivasertib and abiraterone may delay progression and improve disease outcomes.
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study☆
Annals of Oncology | | K. Fizazi, N.W. Clarke, M. De Santis, H. Uemura, A.P. Fay, N. Karadurmus, M. Kwiatkowski, C. Alvarez-Fernandez, S. Jiang, M. Sotelo, D. Parslow, N. Oliveira, T.G. Kwon, D. Ye, S. Boudewijns, P. Danchaivijitr, C. Rooney, C. Gresty, M. Yeste-Velasco, J. Logan, D.J. George, CAPItello-281 Study Group
Topics: prostate-cancer, clinical-trials, research